What is the recommended lamotrigine dosing regimen and monitoring plan for augmenting treatment in adults with obsessive‑compulsive disorder who have had an inadequate response to a full trial of a selective serotonin reuptake inhibitor and cognitive‑behavioral therapy?

Lamotrigine Augmentation in Treatment-Resistant OCD

Lamotrigine augmentation at 100 mg/day can be considered as a third-line option in adults with treatment-resistant OCD who have failed SSRI monotherapy, CBT, and first-line augmentation strategies (antipsychotics, clomipramine, N-acetylcysteine, or memantine), though it has weaker evidence than these preferred options.

Evidence Hierarchy for Treatment-Resistant OCD

The 2019 Nature Reviews Disease Primers guideline establishes a clear treatment hierarchy for SSRI-resistant OCD 1:

First-line augmentation strategies:

• Antipsychotics (risperidone, aripiprazole) - most commonly used with established efficacy
• Clomipramine - superior to quetiapine in head-to-head trials
• N-acetylcysteine - largest glutamatergic evidence base (3 of 5 RCTs positive)
• Memantine - multiple trials demonstrating efficacy

Second-line glutamatergic agents (including lamotrigine):

• Mentioned as having "some evidence of efficacy" but explicitly ranked below the above options 1

Lamotrigine-Specific Evidence

While the guideline mentions lamotrigine among glutamatergic agents evaluated for treatment-resistant OCD, the supporting research evidence is limited:

Efficacy Data:

• One double-blind RCT (2012, n=33): 100 mg/day lamotrigine showed significant improvement in Y-BOCS obsessions (p<0.0001), compulsions (p<0.0001), and total scores (p<0.0001) over 16 weeks 2
• Second RCT (2016, n=53): 100 mg/day lamotrigine demonstrated significant improvements with effect size of 0.54 and mean Y-BOCS reduction of 8.73 points versus 5.07 for placebo 3
• Case reports suggest benefit in highly refractory patients who failed multiple SRI combinations 4, 5

Critical Limitations:

The evidence base for lamotrigine is substantially weaker than for antipsychotics or N-acetylcysteine, with only two small RCTs versus multiple larger trials for preferred agents.

Recommended Dosing Regimen

Titration schedule (based on standard lamotrigine dosing to minimize rash risk, adapted from research protocols 3, 2, 6):

• Weeks 1-2: 25 mg/day
• Weeks 3-4: 50 mg/day
• Weeks 5-8: 100 mg/day (target dose)
• Weeks 9-12: May increase to 150-200 mg/day if inadequate response and good tolerability

Target therapeutic dose: 100 mg/day (most consistent evidence at this dose)

Duration of trial: Minimum 12 weeks at target dose before assessing response 3, 2

Monitoring Plan

Baseline Assessment:

• Y-BOCS score
• Baseline skin examination
• Liver function tests
• Pregnancy test (if applicable - lamotrigine is Category C)
• Document all current medications (especially valproate, which doubles lamotrigine levels)

Ongoing Monitoring:

Weeks 1-8 (titration phase):

• Weekly assessment for rash (Stevens-Johnson syndrome risk ~0.1% in adults with slow titration)
• Instruct patient to immediately report any rash, fever, or flu-like symptoms
• Monitor for dizziness, headache, diplopia

Weeks 8,12, and beyond:

• Y-BOCS scores at weeks 8 and 12
• Response defined as ≥25% reduction in Y-BOCS (some studies use ≥35%)
• Monitor for gastrointestinal symptoms (mild, transient in ~40% of patients) 3
• Assess depressive symptoms (may improve independently) 2, 6

Drug Interactions:

• Valproate: Doubles lamotrigine levels - reduce lamotrigine dose by 50%
• Carbamazepine/phenytoin: Decrease lamotrigine levels - may need higher doses
• SSRIs: No significant pharmacokinetic interactions reported in OCD trials

Clinical Decision Algorithm

Use lamotrigine augmentation when:

1. Patient has documented treatment-resistant OCD (failed ≥2 adequate SSRI trials including one at high dose for ≥12 weeks)
2. Patient has failed or cannot tolerate first-line augmentation:
   • Antipsychotics (metabolic concerns, extrapyramidal symptoms)
   • Clomipramine (cardiac concerns, drug interactions)
   • N-acetylcysteine (lack of response)
   • Memantine (lack of response or unavailable)
3. Patient is maintained on stable SSRI dose
4. No contraindications to lamotrigine (history of serious rash, hepatic impairment)

Do NOT use lamotrigine as:

• First-line augmentation (antipsychotics have stronger evidence)
• Second-line before trying N-acetylcysteine or memantine (larger evidence base)
• In patients taking valproate without dose adjustment
• In patients unable to comply with slow titration or monitoring

Critical Safety Considerations

Major concern: Stevens-Johnson syndrome/toxic epidermal necrolysis risk requires:

• Strict adherence to slow titration schedule
• Immediate discontinuation if any rash develops
• Patient education about warning signs
• Higher vigilance in first 8 weeks

The slow titration requirement means clinical benefit may not be apparent until 12-16 weeks after initiation, which is longer than antipsychotic augmentation (typically 4-8 weeks).

Comparative Context

Recent 2026 meta-analysis data confirms the treatment hierarchy: antipsychotic augmentation (particularly risperidone and aripiprazole) demonstrates superior efficacy with haloperidol showing largest effect (SMD = -1.34) but poor tolerability, while risperidone (SMD = -0.74) and aripiprazole (SMD = -0.57) offer optimal efficacy-tolerability balance 7. Lamotrigine's effect size of 0.54 3 is modest in comparison, supporting its position as a later-line option.

Bottom line: Lamotrigine augmentation at 100 mg/day is a reasonable third-line strategy with acceptable tolerability, but clinicians should exhaust better-evidenced options first and maintain realistic expectations about response rates and timeline to benefit.